A Phase 2 interventional study of KER-047 in Iron Deficiency Anemia, sponsored by Keros Therapeutics, Inc.. Withdrawn at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.
Sponsored by Keros Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Anemia, Iron-Deficiency with a site in Israel — 1 open to participants now, 1 under way, none of them phase 3. Anemia, Iron-Deficiency · Israel.
Among the 10 studies in Anemia, Iron-Deficiency with a site in Israel, this one is one of 2 that started in 2023, is the only one in phase 2, and was the 9th registered.
602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.
Browse Anemia, Iron-Deficiency studies →1 of the 10 studies in Anemia, Iron-Deficiency with a site in Israel is open now. Recruiting first, the newest first:
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–50 · Women only
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 38 across the 6 interventional studies, 600 across the 3 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 9 most frequent:
Keros Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Keros Therapeutics, Inc. has 1 study filed under Anemia, Iron-Deficiency — fewer than ten, so there is no comparison to draw.
1 of the studies in Anemia, Iron-Deficiency with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06061393Western Galilee Hospital-NahariyaComparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Anemia, Iron-Deficiency with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to explore the safety and preliminary efficacy of a response-guided dose titration of KER-047 in the treatment of functional IDA (Iron deficiency anemia) in MDS (Myelodysplastic syndrome), MF(Myelofibrosis), and MDS/MPN (Myeloproliferative neoplasm) overlap syndromes.
This is a Phase 2 multicenter, open-label study being conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of response-guided dose titration of KER-047 in adult participants with functional iron deficiency anemia (IDA) associated with myelodysplastic syndrome (MDS), myelofibrosis (MF), and myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Approximately 20 patients will be enrolled. Dosing of KER-047 may be adjusted based on safety/tolerability and treatment response. The study will be conducted in 2 parts: Part 1 Initial Titration Strategy and Part 2 Cohort Expansion or Alternate Titration Strategy.
The total planned duration of participation for an individual participant is approximately 32 weeks (4-week screening phase, 24-week treatment period, and 4-week follow-up period). For participants in the extension phase, the maximum duration of participation would be approximately 104 weeks (2 years) (4-week screening phase, 24-week treatment period, 18 month [72 weeks] extension period, and 4-week follow-up period).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
One of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
KER-047(30 mg, 60mg or 80mg) oral tablet daily (or every other day) for up to 24 weeks.
Drug: KER-047
The starting dose regimen and titration schedule of KER-047 oral tablet will be based on the SRC (Safety Review Committee) recommendation from Part 1.
Drug: KER-047
Oral tablet, daily (or every other day) administration
Percentage of participants experiencing Treatment-emergent adverse events (TEAEs)
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Dose limiting toxicities (DLTs)
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Percentage of participants experiencing Treatment-related AEs (Adverse events)
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Number of participants discontinuing due to AEs (Adverse events)
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Change from Baseline in clinical laboratory values
To determine the safety and tolerability based on changes from baseline in select clinical laboratory parameters including: Alkaline phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Glucose, Potassium, Sodium, Total bilirubin, Folate, WBC count, Platelet Count, Reticulocyte Count, Transferrin Saturation percentage. Note - Select safety parameters will be listed as separate outcomes during results update.
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Systolic Blood Pressure
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Diastolic Blood Pressure
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Respiratory rate
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Heart rate
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Body temperature
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Fridericia corrected QT interval via 12-lead Electrocardiogram (ECG)
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
QT interval via 12-lead Electrocardiogram (ECG)
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
QRS interval via 12-lead Electrocardiogram (ECG)
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
PR interval via 12-lead Electrocardiogram (ECG)
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Body weight (in kg)
To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Change from baseline in reticulocyte hemoglobin content (RET-He)
To evaluate the Pharmacodynamic (PD) effects of KER-047 on iron metabolism in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Change from baseline in hepcidin concentration
To evaluate the Pharmacodynamic (PD) effects of KER-047 on iron metabolism in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Change from baseline in hemoglobin (Hgb)
To evaluate the effect of KER-047 on anemia in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Proportion of participants who have Hgb increase of ≥1.0 g/dL (0.6 mmol/L)
To evaluate the effect of KER-047 on anemia in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Proportion of participants who have Hgb increase of ≥1.5 g/dL (0.9 mmol/L)
To evaluate the effect of KER-047 on anemia in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension
Proportion of RBC-transfused participants who achieve ≥8 weeks of transfusion independence during any consecutive period up to End of Treatment
To evaluate the effect of KER-047 on anemia in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 29 weeks or up to 101 weeks if in the treatment extension
Plasma KER-047 and any metabolites concentration, summarized by time point
To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Week 1 and Week 13 in Part 1 and 2
Estimated peak plasma concentration (Cmax)
To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Week 1 and Week 13 in Part 1 and 2
Time to peak plasma concentration (Tmax)
To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Week 1 and Week 13 in Part 1 and 2
Area under the plasma KER-047 concentration curve (AUClast)
To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Week 1 and Week 13 in Part 1 and 2
Mean trough (Ctrough) plasma KER-047 and metabolites of interest concentration
To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 25 weeks
Plasma KER-047 and metabolites of interest accumulation (Rac)
To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 25 weeks
Determination of steady-state (as appropriate)
To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes
Time frame: Up to 25 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2023; primary completion for Aug 2025, 20 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Keros Therapeutics, Inc.